These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 1654202)
1. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Kushner BH; Cheung NK Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Munn DH; Cheung NK Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978 [TBL] [Abstract][Full Text] [Related]
3. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Kushner BH; Cheung NK Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466 [TBL] [Abstract][Full Text] [Related]
4. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Kushner BH; Cheung NK Blood; 1992 Mar; 79(6):1484-90. PubMed ID: 1347707 [TBL] [Abstract][Full Text] [Related]
5. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723 [TBL] [Abstract][Full Text] [Related]
6. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368 [TBL] [Abstract][Full Text] [Related]
7. Effects of granulocytes on human neuroblastoma cells measured by chemiluminescence and chromium-51 release assay. Bruchelt G; Handgretinger R; Kimmig A; Goeke B; Siedner R; Reisfeld RA; Niethammer D; Treuner J J Biolumin Chemilumin; 1989; 3(2):93-6. PubMed ID: 2728918 [TBL] [Abstract][Full Text] [Related]
8. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils. Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113 [TBL] [Abstract][Full Text] [Related]
9. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079 [TBL] [Abstract][Full Text] [Related]
10. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
11. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822 [TBL] [Abstract][Full Text] [Related]
12. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Barker E; Reisfeld RA Cancer Res; 1993 Jan; 53(2):362-7. PubMed ID: 8417829 [TBL] [Abstract][Full Text] [Related]
13. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Helfand SC; Hank JA; Gan J; Sondel PM Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851 [TBL] [Abstract][Full Text] [Related]
14. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Cheung NK; Modak S Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541 [TBL] [Abstract][Full Text] [Related]
15. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933 [TBL] [Abstract][Full Text] [Related]
16. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994 [TBL] [Abstract][Full Text] [Related]
17. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Mujoo K; Cheresh DA; Yang HM; Reisfeld RA Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030 [TBL] [Abstract][Full Text] [Related]
18. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646 [TBL] [Abstract][Full Text] [Related]
19. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876 [TBL] [Abstract][Full Text] [Related]